| PDF (285kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-220429
- DOI to cite this document:
- 10.5283/epub.22042
Abstract
The pharmacokinetics of torasemide, a new loop diuretic, as well as its active metabolites M1 and M3, and its inactive main metabolite, M5, were studied in 12 patients with end-stage renal failure during single i.v. (n = 6) or single oral (n = 6) dosing of 200 mg torasemide, and during chronic oral treatment for 9 days (n = 12). The elimination half-life (t1/2) of torasemide was unchanged in ...
Owner only: item control page